SCHEMBL13833701

SCHEMBL13833701

CCOC(=O)c1oc2ccccc2c1-c1nc2ccccc2s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 11/20 0.53
▸ AHR P35869 1/20 0.53
▸ PLK1 P53350 1/20 0.51
▸ MAPT P10636 8/20 0.50
▸ ALDH1A1 P00352 6/20 0.50
▸ THRB P10828 1/20 0.50
▸ MEN1 O00255 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ TP53 P04637 1/20 0.48
▸ ALOX12 P18054 1/20 0.48
▸ STAT3 P40763 1/20 0.48
▸ LMNA P02545 1/20 0.47
▸ NPSR1 Q6W5P4 3/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ TSHR P16473 5/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ HSD17B10 Q99714 2/20 0.45
▸ GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13833704 0.81 MAPT (0.60) KDM4EMAPTALDH1A1THRBMEN1
SCHEMBL17779076 0.76 ALDH1A1 (0.71) KDM4EMAPTALDH1A1MEN1KMT2A
SCHEMBL8871762 0.76 KDM4E (0.70) KDM4EAHRPLK1MAPTALDH1A1
SCHEMBL13833795 0.74 MAPT (0.55) KDM4EMAPTALDH1A1THRBMEN1
SCHEMBL4298781 0.72 RARA (0.64) KDM4EMAPTALDH1A1MEN1KMT2A
SCHEMBL694406 0.72 NPSR1 (0.66) KDM4EMAPTALDH1A1MEN1KMT2A
SCHEMBL719242 0.72 KDM4E (0.78) KDM4EAHRPLK1MAPTALDH1A1
SCHEMBL13822671 0.71 MAPT (0.45) KDM4EMAPTALDH1A1THRBMEN1
SCHEMBL3397941 0.71 ALDH1A1 (0.51) KDM4EMAPTALDH1A1MEN1KMT2A
SCHEMBL6964091 0.71 KDM4E (0.71) KDM4EAHRPLK1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130072473-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS PROTEOSTASIS THERAPEUTICS, INC. 2013-03-21 — — US disclosed
US-20130072473-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS PROTEOSTASIS THERAPEUTICS, INC. 2013-03-21 — — US disclosed
US-20130072473-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS PROTEOSTASIS THERAPEUTICS, INC. 2013-03-21 — — US disclosed
WO-2012154888-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS PROTEOSTASIS THERAPEUTICS, INC. (US) 2012-11-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072473-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS HSPA5, PSMG3, VCP KDM4E 3155/4885AHR 3451/4885PLK1 2022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback